1
|
Omarini C, Bettelli S, Caprera C, Manfredini S, Caggia F, Guaitoli G, Moscetti L, Toss A, Cortesi L, Kaleci S, Maiorana A, Cascinu S, Conte PF, Piacentini F. Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. Cancer Biol Ther 2018; 19:879-886. [PMID: 30067438 DOI: 10.1080/15384047.2018.1480287] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Abstract
BACKGROUND HER2+ metastatic breast cancer (MBC) is a poor prognosis disease, unusually curable. To date, no predictive factors have been clearly correlated with long-term response to anti-HER2 agents. METHODS 54 HER2+ MBC patients treated with HER2 targeted therapy as first line treatment were analysed: 40 with a time to progression longer than 3 years in Long Responders (LR) group and 14 with a progression disease within one year of anti-HER2 therapy in a control group named Early Progressors (EP). The expression of 770 genes and 13 molecular pathways were evaluated using Nanostring PanCancer pathway panel performed on FFPE BC tissues. RESULTS Considering baseline patients and tumor characteristics, EP women had more CNS spread and more metastatic burden of disease compared to LR (p > 0.05). Gene expression analysis identified 30 genes with significantly different expression in the two cohorts; five were driver genes (BRCA1, PDGFRA, AR, PHF6 and MSH2). The majority of these genes were over-expressed, mainly in LR patients, and encoded growth factors, pro- or anti-inflammatory interleukins and DNA repair factors. Only four genes were down regulated, all in EP group (TNFSF10, CACNG1, IL20RB and BRCA1). Most of these genes were involved in MAPK and PI3K pathways. MAPK pathway was differently expressed between LR and EP (p = 0.05). PI3K was the only pathway overexpressed in EP patients. CONCLUSIONS Whole genome expression analysis comparing LR vs. EP identified a group of genes that may predict more favourable long-term outcomes. Up-regulation of MAPK and down-regulation of PI3K pathway could be a positive predictive factors. Further clinical implications are warranted. ABBREVIATIONS BC: breast cancer; MBC: metastatic breast cancer; LR: long responder; EP: early progressor; FFPE: formalin-fixed paraffin-embedded; CNS: central nervous system; PFS: progression free survival; OS: overall survival.
Collapse
Affiliation(s)
- Claudia Omarini
- a Division of Medical Oncology, Department of Medical and Surgical Sciences for Children & Adults , University Hospital of Modena , Modena , Italy
| | - Stefania Bettelli
- b Division of Pathological Anatomy, Department of Diagnostic, Clinical Medicine and Public Health , University Hospital of Modena , Modena , Italy
| | - Cecilia Caprera
- b Division of Pathological Anatomy, Department of Diagnostic, Clinical Medicine and Public Health , University Hospital of Modena , Modena , Italy
| | - Samantha Manfredini
- b Division of Pathological Anatomy, Department of Diagnostic, Clinical Medicine and Public Health , University Hospital of Modena , Modena , Italy
| | - Federica Caggia
- a Division of Medical Oncology, Department of Medical and Surgical Sciences for Children & Adults , University Hospital of Modena , Modena , Italy
| | - Giorgia Guaitoli
- a Division of Medical Oncology, Department of Medical and Surgical Sciences for Children & Adults , University Hospital of Modena , Modena , Italy
| | - Luca Moscetti
- a Division of Medical Oncology, Department of Medical and Surgical Sciences for Children & Adults , University Hospital of Modena , Modena , Italy
| | - Angela Toss
- a Division of Medical Oncology, Department of Medical and Surgical Sciences for Children & Adults , University Hospital of Modena , Modena , Italy
| | - Laura Cortesi
- a Division of Medical Oncology, Department of Medical and Surgical Sciences for Children & Adults , University Hospital of Modena , Modena , Italy
| | - Shaniko Kaleci
- b Division of Pathological Anatomy, Department of Diagnostic, Clinical Medicine and Public Health , University Hospital of Modena , Modena , Italy
| | - Antonino Maiorana
- b Division of Pathological Anatomy, Department of Diagnostic, Clinical Medicine and Public Health , University Hospital of Modena , Modena , Italy
| | - Stefano Cascinu
- a Division of Medical Oncology, Department of Medical and Surgical Sciences for Children & Adults , University Hospital of Modena , Modena , Italy
| | - Pier Franco Conte
- c Department of Surgery, Oncology, and Gastroenterology , University of Padova , Padova , Italy
| | - Federico Piacentini
- a Division of Medical Oncology, Department of Medical and Surgical Sciences for Children & Adults , University Hospital of Modena , Modena , Italy
| |
Collapse
|
2
|
Martinelli E, Sforza V, Cardone C, Capasso A, Nappi A, Martini G, Napolitano S, Rachiglio AM, Normanno N, Cappabianca S, Reginelli A, Bisceglie MD, Latiano TP, Maiello E, Orditura M, De Vita F, Morgillo F, Ciardiello F, Troiani T. Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. ESMO Open 2017; 2:e000177. [PMID: 29211816 PMCID: PMC5703385 DOI: 10.1136/esmoopen-2017-000177] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2017] [Revised: 03/14/2017] [Accepted: 03/15/2017] [Indexed: 12/19/2022] Open
Abstract
Please click here to see linked paper
Collapse
Affiliation(s)
- Erika Martinelli
- Oncologia Medica, Dipartimento di Internistica Clinica e Sperimentale 'F. Magrassi e A. Lanzara', Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy
| | - Vincenzo Sforza
- Oncologia Medica, Dipartimento di Internistica Clinica e Sperimentale 'F. Magrassi e A. Lanzara', Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy
| | - Claudia Cardone
- Oncologia Medica, Dipartimento di Internistica Clinica e Sperimentale 'F. Magrassi e A. Lanzara', Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy
| | - Anna Capasso
- Division of Medical Oncology, School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA
| | - Anna Nappi
- Gastrointestinal Medical Oncology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione Giovanni Pascale'-IRCCS, via Mariano Semmola, Napoli, Italy
| | - Giulia Martini
- Oncologia Medica, Dipartimento di Internistica Clinica e Sperimentale 'F. Magrassi e A. Lanzara', Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy
| | - Stefania Napolitano
- Oncologia Medica, Dipartimento di Internistica Clinica e Sperimentale 'F. Magrassi e A. Lanzara', Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy
| | | | - Nicola Normanno
- Cell Biology and Preclinical Models Unit, INT-Fondazione Pascale, Napoli, Italy
| | - Salvatore Cappabianca
- Department of Radiology, Università degli Studi della Campania Luigi Vanvitelli, piazza Miraglia, Napoli, Italy
| | - Alfonso Reginelli
- Department of Radiology, Università degli Studi della Campania Luigi Vanvitelli, piazza Miraglia, Napoli, Italy
| | | | - Tiziana Pia Latiano
- Oncology Unit, Istituto di Ricovero e Cura a Carattere Scientifico Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
| | - Evaristo Maiello
- Oncology Unit, Istituto di Ricovero e Cura a Carattere Scientifico Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
| | - Michele Orditura
- Oncologia Medica, Dipartimento di Internistica Clinica e Sperimentale 'F. Magrassi e A. Lanzara', Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy
| | - Fernando De Vita
- Oncologia Medica, Dipartimento di Internistica Clinica e Sperimentale 'F. Magrassi e A. Lanzara', Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy
| | - Floriana Morgillo
- Oncologia Medica, Dipartimento di Internistica Clinica e Sperimentale 'F. Magrassi e A. Lanzara', Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy
| | - Fortunato Ciardiello
- Oncologia Medica, Dipartimento di Internistica Clinica e Sperimentale 'F. Magrassi e A. Lanzara', Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy
| | - Teresa Troiani
- Oncologia Medica, Dipartimento di Internistica Clinica e Sperimentale 'F. Magrassi e A. Lanzara', Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy
| |
Collapse
|